TNGX FY 2021 Earnings — Tango Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TNGXTango Therapeutics, Inc.

$2B

FY 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$37M+383.8% YoY

Gross Profit

$37M100.0% margin

Operating Income

-$58M-157.1% margin

Net Income

-$58M-157.2% margin

EPS (Diluted)

$-0.94

Cash Flow

Operating Cash Flow

-$60M

Free Cash Flow

-$61M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$500M

Total Liabilities

$155M

Stockholders' Equity

$345M

Cash & Equivalents

$143M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$37M	$8M	+383.8%
Gross Profit	$37M	$6M	+514.2%
Operating Income	-$58M	-$52M	-11.5%
Net Income	-$58M	-$52M	-12.1%